| Stereochemistry | ABSOLUTE |
| Molecular Formula | C18H26FNO4 |
| Molecular Weight | 339.4017 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]1(CNCCO1)[C@@](O)(CC2=CC(F)=CC=C2OC)C3CCOCC3
InChI
InChIKey=CPBHSHYQQLFAPW-ZWKOTPCHSA-N
InChI=1S/C18H26FNO4/c1-22-16-3-2-15(19)10-13(16)11-18(21,14-4-7-23-8-5-14)17-12-20-6-9-24-17/h2-3,10,14,17,20-21H,4-9,11-12H2,1H3/t17-,18+/m0/s1
| Molecular Formula | C18H26FNO4 |
| Molecular Weight | 339.4017 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Edivoxetine (LY-2216684) is a highly selective norepinephrine reuptake inhibitor. It is under development as adjunctive or monotherapy of disorders believed to be associated with alterations in norepinephrine transmission within the central nervous system. Currently, edivoxetine is being studied in the treatment of attention-deficit hyperactivity disorder. Edivoxetine development in the treatment of major depressive disorder has been discontinued.
CNS Activity
Originator
Approval Year
PubMed
Sample Use Guides
Open-label study of edivoxetine once daily dosing (0.1-0.3âmg/kg) as treatment for ADHD in children (6-11 years) and adolescents (12-17 years) to assess safety for up to 5 years.
The efficacy, tolerability, and safety of edivoxetine were studied in adult patients with major depressive disorder (MDD). This randomized, double-blind study compared flexible-dose edivoxetine 6-18 mg once daily with placebo for 10 weeks acute therapy followed by 1 year edivoxetine treatment
Route of Administration:
Oral
|
|
SALT/SOLVATE -> PARENT |
|
Showing 1 to 1 of 1 entries
